Equities

Ortivus AB

Ortivus AB

Actions
  • Price (SEK)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ortivus AB is a Sweden-based provider of mobile solutions for modern emergency medical services. The Company is engaged in the development of mobile surveillance and communication solutions, forming a decision support system. Its offering comprises: MobiMed Smart, a decision support system, which allows ambulance personnel to handle documentation, monitoring and introduce a structured approach in prehospital care; CoroNet, a mobile surveillance solution which allows patients to move freely under supervision of medical staff and provides healthcare professionals with monitoring information. In addition, the Company provides a wide range of services, such as support, implementation, training and consulting, among others. The Company’s customer base includes mainly ambulance services and emergency departments.

  • Revenue in SEK (TTM)75.12m
  • Net income in SEK-24.17m
  • Incorporated1985
  • Employees38.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.